Why Charles River Laboratories International, Inc. (CRL) stock moved
Updated Oct 11, 2026
Charles River Laboratories International, Inc. (CRL) shares rose 1.3% to $301.79 as of October 11, 2026, a modest gain from the prior close of $298.00. BestStocks flagged the session as a major change for CRL. The move is tied to company news. Below, we break down what changed for CRL, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
Company News
Charles River launched Apollo Orchestrate, a digital platform capability connecting and automating laboratory execution systems. Automation capability strengthens CRL's competitive moat in drug discovery services and improves operational efficiency.
This summary describes the catalyst and move as first detected on Oct 6, 2026, 10:16 AM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
NewsWeak confidence
Rel. volume
0.7×
Below Avg
Vs peers
—
No comparable peers
Market cap
$14.5B
New York Stock Exchange
Analyst target
$306
+1.2% vs price
Price chart
Sep 10 – Oct 9
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Charles River Laboratories International, Inc. investors
For Charles River Laboratories International, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 1.3% session move; Charles River Laboratories International, Inc. (CRL) moved +3.50% from $267.62 to $277.00 on 2026-08-10, reaching a new 30-day high. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $305.50, implying +1.2% upside from $301.79. Over the past 90 days analysts logged 1 upgrade and 1 downgrade. BestStocks rates the overall signal quality weak (38/100). With earnings roughly 24 days out, the next report is the most likely near-term test of the move.
CRL price reaction
CRL last traded at $301.79, up $3.79 (+1.27%) from the previous close of $298.00. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $272.88 and $310.77, and it currently sits about 76% of the way up that band.
Bullish and bearish analyst opinions on Charles River Laboratories International, Inc. (CRL)
The consensus analyst price target on Charles River Laboratories International, Inc. (CRL) is $305.50, 1.2% above the recent $301.79. Over the past 90 days analysts logged 1 upgrade, 14 maintains, and 1 downgrade. Here is how the bullish and bearish cases on CRL line up.
▲ The bullish case
+Wall Street's consensus price target of $305.50 implies +1.2% upside from $301.79.
+The Street's most bullish target is $357.00 (+18.3%).
+1 analyst upgrade in the past 90 days, most recently JP Morgan to Overweight (2026-08-06).
+Positive 1.3% session move.
+Charles River Laboratories International, Inc. (CRL) moved +3.50% from $267.62 to $277.00 on 2026-08-10, reaching a new 30-day high.
▼ The bearish case
−The most bearish analyst target is $219.00 (-27.4%).
−1 analyst downgrade in the past 90 days, most recently CLSA to Hold (2026-07-20).
−Charles River Laboratories International, Inc. (CRL) moved −2.71% from $267.99 to $260.72 on August 5, 2026.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 10, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Charles River Laboratories stock rose 4.62% to $303.59, driven by continued positive investor momentum following the company's recent Investor Day, where management raised its 2026 earnings outlook and projected 5–7% annual organic revenue growth through 2030 with targeted operating margins near 24% (finance.yahoo.com). The gain reflects analyst upgrades and stabilizing client bookings after a period of drug discovery project cancellations.
News2026-09-30-0.3%
Analysts assign CRL average price target of $290 with moderate buy consensus from 17 firms.
Charles River Laboratories International, Inc. moved +6.92% intraday from $277.33 to $296.52. Charles River Laboratories (NYSE: CRL) stock jumped roughly 6% to 7% on September 24, 2026, driven by bullish updates delivered at the company's 2026 Investor Day presentation. ### 📈 Investor Day Catalysts - 2026 Guidance Upgraded: Management announced that full-year revenue and non-GAAP EPS are tracking toward the upper ends of previous guidance ranges. - Stronger Demand: The upgrade reflects a sustained favorable demand uptick from biopharmaceutical clients. - 2030 Long-Term Targets: - Targeting organic compound annual revenue growth of 5% to 7% from 2027 through 2030. - Aimed for an operating margin approaching 24%. - Cost Savings Program: Unveiled plans for the "Create the Future" efficiency initiative, targeting over $300 million in cumulative savings through 2030. - Pathway to Purpose: Outlined a refreshed strategic vision to modernize operations and optimize the client experience. Would you like a breakdown of how Charles River's valuation metrics and analyst price targets look following these updated 2030 projections?
Filings2026-09-24+6.2%
Charles River Laboratories International, Inc. (CRL) filed a new 8-K on September 24, 2026. The filing content was not detailed in available sources.
Material / Earnings2026-08-20+0.5%
Charles River Laboratories International, Inc. (CRL) moved +2.01% from $285.72 to $291.45 on 2026-08-20, reaching a new 30-day high. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Material / Earnings2026-08-19+3.9%
Charles River Laboratories International, Inc. (CRL) moved +2.29% from $283.50 to $290.00 on 2026-08-19, reaching a new 30-day high. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Material / Earnings2026-08-18-2.6%
Charles River Laboratories International, Inc. (CRL) moved −2.52% from $286.40 to $279.19 on 2026-08-18. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average at 0.7x, indicating the move occurred on typical trading activity.
In-depth CRL event analyses
Permanent, dated analyses of CRL's most significant sessions.
Why did Charles River Laboratories International, Inc. (CRL) stock move?
CRL rose 1.3% to $301.79. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did CRL stock rise?
CRL gained 1.27% ($3.79) versus the prior close of $298.00, last trading at $301.79 on 0.7× average volume.
When is Charles River Laboratories International, Inc.'s next earnings date?
CRL's next earnings report is estimated for 2026-11-04 — about 24 days away.
What is the analyst price target for CRL?
The consensus analyst price target for CRL is $305.50, about 1.2% above the current $301.79. Over the past 90 days, analysts recorded 1 upgrade, 14 maintains, and 1 downgrade.
How BestStocks tracks CRL
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for CRL, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 11, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
